Leap Therapeutics, Inc. (Nasdaq: LPTX) unveiled a sweeping strategic pivot today: the oncology company is rebranding as Cypherpunk Technologies Inc., has already purchased ~$50 million of Zcash (ZEC) for a new digital‑asset treasury strategy, and will switch its Nasdaq ticker from LPTX to CYPH at the open on Thursday, Nov. 13, 2025. The company also filed fresh SEC documents, including Q3 2025 results and a $200 million at‑the‑market (ATM) equity program with Cantor Fitzgerald.
- New name & ticker: Leap Therapeutics → Cypherpunk Technologies Inc.; CYPH begins trading Nov. 13; LPTX remains active today.
- Treasury strategy: Company confirms 203,775.27 ZEC purchased at a $245.37 average price (≈ $50M).
- Leadership changes:Khing Oei named Chairman; Will McEvoy appointed Chief Investment Officer and director.
- Q3 2025 results:Net loss $3.3M vs. $18.2M a year ago; R&D $1.2M vs. $14.9M as trial spending declined.
- ATM facility: Up to $200M of common shares via Cantor; last reported price on Nov. 11 was $0.4375; 56,651,840 shares outstanding as of Nov. 11 (before warrants/RSUs).
- Special meeting set:Dec. 15, 2025 vote on increasing authorized shares, reverse‑split authority (1‑for‑5 to 1‑for‑20), a 2025 equity plan, and Nasdaq 5635 share‑issuance approval tied to October’s financing.
What changed — and why it matters
Rebrand & crypto‑treasury pivot. In a 7:00 a.m. ET release, the company said it will adopt the Cypherpunk Technologies name to reflect a strategy focused on building a Zcash‑denominated treasury while continuing development of its cancer programs (notably sirexatamab/DKN‑01 and FL‑501). Management disclosed it has spent $50M of October’s private‑placement proceeds to buy ~203.8K ZEC at a $245.37 average. Trading under “CYPH” starts Nov. 13. PR Newswire
Leadership refresh. The board appointed Khing Oei as non‑executive Chair and Will McEvoy as Chief Investment Officer and director, effective Nov. 11, aligning governance with the new treasury strategy. An accompanying Form 8‑K details the name change, ticker change timing, and award/RSU arrangements tied to the leadership transition.
Structure of the business. While the parent company takes the Cypherpunk name, the biotech operations will run in a wholly owned subsidiary also called “Leap Therapeutics, Inc.”, preserving continuity for the drug pipeline and clinical/regulatory interactions. PR Newswire+1
Fresh filings: Q3 2025, 8‑K, and a $200M ATM
Quarterly results & lower burn. In its 8:00 a.m. ET update and concurrent 10‑Q, the company reported Q3 2025 net loss of $3.3M (vs. $18.2M in Q3 2024) and R&D of $1.2M (vs. $14.9M), reflecting a deliberate wind‑down of prior trials and expense reductions. Management also highlighted final Phase 2 data presented at ESMO 2025 for sirexatamab + bevacizumab + chemo in MSS colorectal cancer, with statistically significant outcomes in DKK1‑high subsets.
The 10‑Q notes cash & equivalents of roughly $9.7M at Sept. 30, 2025 (before the October financing proceeds allocated to operations) and recaps the October PIPE terms and board‑designation rights for the lead investor.
At‑the‑market (ATM) offering. A same‑day 424B5 prospectus supplement established an ATM program for up to $200M of common stock to be sold from time to time through Cantor Fitzgerald (commission up to 3%). The filing reiterates the planned ticker change to CYPH on or about Nov. 13, shows 56,651,840 shares outstanding (Nov. 11), and breaks out substantial pre‑funded and common warrants outstanding from October’s financing (e.g., 80.77M pre‑funded warrants at $0.001 and 71.99M common warrants at $0.5355), highlighting potential future dilution.
8‑K: Confirms name change effective Nov. 12, ticker switch expected Nov. 13, the $50M ZEC purchase, establishment of a new wholly owned “Leap Therapeutics, Inc.” subsidiary to house R&D, and additional governance/compensation details. SEC
Market reaction (intraday)
LPTX shares spiked on heavy volume following the rebrand and treasury disclosure. As of the latest intraday print, the stock was trading around $0.95, having touched an intraday high near $1.07 (vs. a Nov. 11 close of $0.4375), for an approximately +118% move at peak. Volume has surged well above typical averages.
What this means for current shareholders
- No action required for the ticker change. Shares you hold today as LPTX will continue to exist; the symbol automatically updates to CYPH on Nov. 13. The 8‑K indicates no shareholder vote was required for the name change under Delaware law.
- Biotech work continues. Oncology R&D (sirexatamab/DKN‑01, FL‑501) continues in the “Leap Therapeutics, Inc.” subsidiary, while the parent pursues the Zcash treasury strategy. PR Newswire
- Expect higher equity issuance flexibility. The Dec. 15, 2025special meeting seeks approvals including increasing authorized shares, reverse‑split discretion (1:5–1:20), a 2025 equity plan, and Nasdaq 5635 share‑issuance approval related to the October PIPE. These proposals, if approved, would give the company more room to raise equity—especially relevant in light of the newly filed $200M ATM.
Key quotes from management (from today’s releases)
- CEO Douglas E. Onsi framed the move as “a transformational step” to advance active participation in Zcash while progressing oncology programs. PR Newswire
- CIO Will McEvoy emphasized building a “value‑aligned” investor base for the treasury strategy rather than short‑term financing, signaling a long‑term orientation. PR Newswire
Risks and what to watch next
- Crypto sensitivity: The 424B5 warns that the stock could become correlated with ZEC price volatility and that digital‑asset regulatory uncertainty is material.
- Dilution overhang: Outstanding pre‑funded/common warrants from the October financing, plus the $200M ATM, represent potential dilution if exercised/issued.
- Listing compliance & corporate actions: Outcomes of the Dec. 15 vote (share increase / reverse split authority) could influence liquidity and Nasdaq compliance.
- Pipeline catalysts: Following ESMO 2025 data, the company plans regulatory engagement for sirexatamab and an update on its registrational pathway in Q1 2026.
Context: How we got here
- Oct. 6, 2025: Company announced $58.888M in PIPE commitments led by Winklevoss Capital to kick‑start the digital‑asset treasury strategy.
- Oct. 9, 2025:PIPE closed; securities included common shares plus large pre‑funded and common warrant tranches.
- Oct. 20, 2025:Final DeFianCe (sirexatamab) Phase 2 results presented at ESMO 2025.
- Nov. 3, 2025:DEF 14A filed, scheduling the Dec. 15 special meeting and outlining proposals.
- Nov. 12, 2025:Rebrand to Cypherpunk, $50M in ZEC disclosed, CYPH ticker timing, Q3 results, 8‑K/10‑Q/424B5 filed.
The bottom line
On Nov. 12, 2025, Leap Therapeutics effectively split its identity: the listed parent becomes Cypherpunk Technologies with a Zcash‑forward treasury, while oncology R&D continues under a Leap Therapeutics subsidiary. With Q3 burn materially lower, a $200M ATM in place, and governance aligned to the new strategy, investors now must price a hybrid story—part crypto‑treasury, part biotech—with near‑term catalysts including the ticker change (Nov. 13) and the Dec. 15 special meeting.
Disclosure: This article is for news and analysis only and is not investment advice.
Primary sources (Nov. 12, 2025): Company press releases (7:00 a.m. ET rebrand; 8:00 a.m. ET Q3), Form 8‑K, Form 10‑Q, and 424B5 prospectus supplement.
